GlassScriptPhysician profile
Judson M Severson
NPI 1801093877
$1,141.72
in general payments reported to CMS, 2019-2025
8 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.08 · 2020: $97.03 · 2021: $24.80 · 2022: $181 · 2023: $208 · 2024: $425 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $277.79 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $172.58 | 2020-2024 | Jynarque |
| Paratek Pharmaceuticals, INC. | $124.99 | 2023 | Nuzyra |
| Veloxis Pharmaceuticals, INC. | $124.96 | 2022 | |
| Genzyme Corporation | $122.88 | 2024 | |
| Ardelyx, INC. | $122.38 | 2024 | Xphozah 30 Mg |
| Aurinia Pharma U.S., INC. | $117.06 | 2021-2024 | Lupkynis |
| W. L. Gore & Associates, INC. | $79.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judson Severson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.